Quality of Recovery After Quadratus Lumborum Block for Cesarean Section.

Quality of Recovery After Quadratus Lumborum Block for Cesarean Section: A Prospective Pilot Study

The aim of this prospective study is to evaluate the recovery after cesarean section in patients who will receive Quadratus Lumborum Block (QLB) as a part of multimodal analgesia using Postoperative quality of recovery scale.

Study Overview

• Status: Completed
• Conditions: Postoperative Pain

Detailed Description

Several researchers had evaluated the effectiveness of QLB in controlling postoperative pain in different patient populations. In these studies, the effectiveness of the QLB was mainly assessed by postoperative pain scores and analgesia consumption, rather than adapting any of the more comprehensive recovery scales .

Postoperative quality of recovery scale (PostopQRS) is a relatively new recovery score, which was first published on 2010, and was designed to be a tool for assessment of multiple domains in recovery. In this assessment tool, recovery was defined as return to the pre-surgery base line scores or better.

The aim of this prospective study is to evaluate the recovery after cesarean section in patients who will receive Quadratus Lumborum Block QLB as a part of multimodal analgesia using Postoperative quality of recovery scale.

• Study Type: Observational
• Enrollment (Actual): 25

Contacts and Locations

Study Locations

• United Arab Emirates
  • Abu Dhabi, United Arab Emirates, 3788
    • Corniche Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

Twenty five parturients, with American Society of Anesthesiologists (ASA) physical status II, with normal singleton pregnancy, at 37 weeks gestation or more, admitted to Corniche Hospital for elective caesarean section under spinal anesthesia

Description

Inclusion Criteria:

American Society of Anesthesiologists (ASA) physical status II, normal singleton pregnancy, 37 weeks gestation or more Scheduled for elective cesarean section

Exclusion Criteria:

• Patients refusing spinal
• Patients with BMI >35 kg/m2).
• Expected difficult surgery (> 3 previous sections, abnormal placentation, prolonged surgery more than 2 hours from skin to end) and Estimated Blood Loss more than 1500).
• Expected difficult spinal anesthesia.
• Abnormal coagulation and other contraindications for spinal anesthesia and/or QLB
• Patient with chronic pain.
• Patient treated from psychosis.
• Patients with communication, language barriers .

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
change from baseline postoperative quality of recovery score	Domains of postoperative recovery score are : The physiologic domain .; The nociceptive domain; The emotive domain .; Activities of daily living; Cognitive domain; Over all patients perspective domain	72 hours

Collaborators and Investigators

• Sponsor: Corniche Hospital
• Investigators: Principal Investigator: Waleed Riad, MD, Corniche Hospital; Principal Investigator: Amr Maher, MD, Corncihe hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2018
• Primary Completion (Actual): September 15, 2019
• Study Completion (Actual): October 1, 2019

Study Registration Dates

• First Submitted: March 19, 2018
• First Submitted That Met QC Criteria: May 3, 2018
• First Posted (Actual): May 4, 2018

Study Record Updates

• Last Update Posted (Actual): September 16, 2020
• Last Update Submitted That Met QC Criteria: September 15, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative
• Other Study ID Numbers: Ch1712171

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No